Get Moving! (Yes, Even if You Have Cancer)
June 26, 2018
Brain Stimulation in MS Patients May Work Best at Slower Rate, Study Says
June 26, 2018
Show all

Why Egypt Is at the Forefront of Hepatitis C Treatment

Learn how Egypt has made so much progress against hepatitis C.

Just five years ago, with the best medical therapies available, the odds of curing a person infected with hepatitis C were no better than a coin toss. Eliminating the disease from a whole country was unthinkable.

But today, Egypt is wiping the disease from its population at an unprecedented pace. The effort was made possible by revolutionary new drugs—but no country, including the United States, has come close to deploying them at equivalent scale. Egypt has shown that dramatic improvements in public health are possible when drugs are priced affordably—and a government makes an effort to systematically deploy them. But Egypt is also the exception that proves the rule that while modern society has proven capable of developing transformative medical innovations, it’s far less proficient at maximizing their use.

The hepatitis C epidemic in Egypt—the country with the highest prevalence of the disease in the world—started around 50 years ago, when the government was attempting to get rid of one plague and ended up substituting it for another. For millennia the Nile Delta has been an ideal breeding ground for schistosomiasis, a parasite spread to humans by freshwater snails. In the mid-20th century, the Egyptian government conducted multiple mass-treatment campaigns using an injectable emetic—and needles were repeatedly reused. Hepatitis C virus, not yet known but transmitted efficiently by blood, was inadvertently spread to many citizens. By 2008, one in 10 Egyptians had chronic hepatitis C.

Read on: Why Egypt Is at the Forefront of Hepatitis C Treatment – The Atlantic 

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.